Tofe A J, Francis M D, Harvey W J
J Nucl Med. 1975 Nov;16(11):986-9.
A total of 1,355 patients from clinical trails with the 99mTc-labeled bone agent, Osteoscan (99mTc-Sn -EHDP), has shown a higher incidence of skeletal abnormalities than previously reported. Overall in this study, 60% of bone scans were abnormal in patients with nonosseous neoplasms. Carcinoma of breast, lung, and prostate yielded 67%, 64%, and 62% skeletal involvement, respectively. Over 50% of all the skeletal abnormalities for the neoplastic indications were detected in the thorax and vertebra while the skull, pelvis, and extremities accounted for 22%, 38%, and 34%, respectively.
共有1355例参与使用99mTc标记的骨显像剂Osteoscan(99mTc-Sn-EHDP)的临床试验患者,其骨骼异常发生率高于先前报道。在本研究中,总体而言,非骨肿瘤患者中60%的骨扫描结果异常。乳腺癌、肺癌和前列腺癌患者的骨骼受累率分别为67%、64%和62%。在所有肿瘤相关指征的骨骼异常中,超过50%出现在胸部和脊椎,而颅骨、骨盆和四肢分别占22%、38%和34%。